Hypertrophic Cardiomyopathy Pilot Study

Oregon Health & Science University (OHSU)

Status: Completed

Conditions: Coronary Artery Disease; Hypertrophic Cardiomyopathy

Treatments: Other: Observational: Arrhythmogenic Substrate

Study type: Observational

Funder types: Other

Identifiers

NCT02806479

15049

Details and patient eligibility

About

This study evaluates mechanisms of arrhythmogenicity in hypertrophic cardiomyopathy, in comparison to patients with well-understood arrhythmogenic substrate (ischemic cardiomyopathy), as well as to individuals free from arrhythmogenic substrate

Enrollment: 40 patients

Sex: All

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosed HCM
• Documented history of sustained ventricular tachyarrhythmia or resuscitated sudden cardiac arrest
• Maximal left ventricular wall thickness of > 30mm
• Extensive fibrosis on cardiac MRI (>15% of total myocardial volume)
• >7.5%/5-year risk of sudden cardiac death as determined by HCM risk-SCD

Exclusion criteria

• age < 18 years
• Pregnancy
• Atrial Fibrillation

Trial design

40 participants in 4 patient groups

Case: Hypertrophic cardiomyopathy

Description:

HCM patients at high risk for ventricular arrhythmia

Treatment:

Other: Observational: Arrhythmogenic Substrate

Control I: Healthy

Description:

Healthy Controls

Control II: Post-MI with arrhythmogenic substrate

Description:

Ischemic cardiomyopathy patients with documented history of ventricular tachyarrhythmia and left ventricular hypertrophy

Treatment:

Other: Observational: Arrhythmogenic Substrate

Control III: VT/VF-free ischemic cardiomyopathy

Description:

Ischemic cardiomyopathy patients without ventricular arrhythmia, as proven by non-inducibility and history of freedom from ventricular tachyarrhythmia during at least one ICD generator life